The purpose of this study was to compare the transdermal transfer proˆles of brand and generic tulobuterol patch formulations and to evaluate possible changes of in vivo kinetics resulting from increased transdermal transfer by means of pharmacokinetic analysis using reported in vitro drug release rate data and plasma drug concentration proˆles. On the assumption that the transdermal transfer rate constant )k2* would be constant )independent of formulation*, the drug release rate constant from patch formulation )k1* was predicted to be almost equal to the k2 value )k1k2* in the brand formulation, but 2-to 4-fold higher than the k2 value )k1ôk2* in the two generic formulations. Under normal conditions, there would be no marked diŠerence in the plasma concentration proˆles among the formulations. However, under conditions where transdermal transfer is increased )that is, higher k2*, the plasma tulobuterol concentration was predicted to increase more rapidly, with higher C max , and then to decrease more rapidly in the elimination phase after applying the generic formulations compared with the brand formulation. These diŠerent behaviors would be seen because the transdermal transfer of the generic formulations would be aŠected by k2, whereas k1 is still rate-determining for the brand formulation. These results suggest that bronchial asthma patients with risk factors for impaired skin barrier function, including atopic dermatitis, long-term treatment with steroids, and advanced age, should be carefully monitored for reduced treatment e‹cacy or adverse drug reactions after application of rapid-release generic tulobuterol patch formulations.
K" e Vd ml ŝD Ϊŕ ŋŉÌ;%Ì k1: drug release rate constant from patch formulation; k2: transdermal transfer rate constant; ke: elimination rate constant from blood; t l : lag time; Vd0F: apparent volume of distribution; Cmax ratio: )C max at 3-fold higher k2*0)Cmax at unaŠected k2*; Tmax ratio: )T max at 3-fold higher k2*0 )T max at unaŠected k2*. The k1 was estimated to be 1 for the original formulation and 4 for the generic formulation. Models of drug release from the formulation and in vivo kinetics at k2ñ1 )A, normal transdermal transfer rate* and at k2ñ3 )3-fold increase* )B, increased transdermal transfer rate* are shown schematically. The graph illustrates the corresponding time course of the plasma concentration. While A shows that there is no marked diŠerence in the time course of the blood concentration between the original and generic formulations, B shows that the generic formulation is associated with an increase in Cmax and a subsequent rapid decrease in the tulobuterol concentration. 
